U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press/Media

Period	26 Oct 2022

Media coverage

Title	U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Media name/outlet	PipelineReview
Country/Territory	Spain
Date	26/10/22
URL	ct.moreover.com/?a=49086932149&p=1gw&v=1&x=2YmTybZ-GBwnM2zxRdWdJQ
Persons	Ajai Chari